Logo image of BIAF

BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock Fundamental Analysis

NASDAQ:BIAF - Nasdaq - US09076W1099 - Common Stock - Currency: USD

0.328  -0.01 (-2.38%)

Fundamental Rating

1

BIAF gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 553 industry peers in the Biotechnology industry. BIAF has a bad profitability rating. Also its financial health evaluation is rather negative. BIAF has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BIAF has reported negative net income.
In the past year BIAF has reported a negative cash flow from operations.
BIAF had negative earnings in each of the past 5 years.
BIAF had a negative operating cash flow in each of the past 5 years.
BIAF Yearly Net Income VS EBIT VS OCF VS FCFBIAF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

BIAF has a worse Return On Assets (-175.55%) than 87.16% of its industry peers.
BIAF has a Return On Equity of -676.56%. This is amonst the worse of the industry: BIAF underperforms 80.83% of its industry peers.
Industry RankSector Rank
ROA -175.55%
ROE -676.56%
ROIC N/A
ROA(3y)-100.74%
ROA(5y)-1117.09%
ROE(3y)-194.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIAF Yearly ROA, ROE, ROICBIAF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

BIAF has a better Gross Margin (34.41%) than 74.32% of its industry peers.
BIAF does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIAF Yearly Profit, Operating, Gross MarginsBIAF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

0

2. Health

2.1 Basic Checks

BIAF does not have a ROIC to compare to the WACC, probably because it is not profitable.
BIAF has more shares outstanding than it did 1 year ago.
The debt/assets ratio for BIAF is higher compared to a year ago.
BIAF Yearly Shares OutstandingBIAF Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
BIAF Yearly Total Debt VS Total AssetsBIAF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

BIAF has an Altman-Z score of -17.29. This is a bad value and indicates that BIAF is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BIAF (-17.29) is worse than 82.28% of its industry peers.
BIAF has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BIAF (0.27) is worse than 71.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z -17.29
ROIC/WACCN/A
WACC9.37%
BIAF Yearly LT Debt VS Equity VS FCFBIAF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

BIAF has a Current Ratio of 0.55. This is a bad value and indicates that BIAF is not financially healthy enough and could expect problems in meeting its short term obligations.
BIAF's Current ratio of 0.55 is on the low side compared to the rest of the industry. BIAF is outperformed by 92.22% of its industry peers.
BIAF has a Quick Ratio of 0.55. This is a bad value and indicates that BIAF is not financially healthy enough and could expect problems in meeting its short term obligations.
BIAF's Quick ratio of 0.53 is on the low side compared to the rest of the industry. BIAF is outperformed by 92.22% of its industry peers.
Industry RankSector Rank
Current Ratio 0.55
Quick Ratio 0.53
BIAF Yearly Current Assets VS Current LiabilitesBIAF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

BIAF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.05%, which is quite impressive.
BIAF shows a strong growth in Revenue. In the last year, the Revenue has grown by 78.33%.
EPS 1Y (TTM)22.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.33%
Revenue 1Y (TTM)78.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-22.97%

3.2 Future

Based on estimates for the next years, BIAF will show a very strong growth in Earnings Per Share. The EPS will grow by 33.43% on average per year.
The Revenue is expected to decrease by -9.73% on average over the next years.
EPS Next Y51.22%
EPS Next 2Y33.43%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-32.09%
Revenue Next 2Y-9.73%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

BIAF Yearly Revenue VS EstimatesBIAF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2M 4M 6M 8M
BIAF Yearly EPS VS EstimatesBIAF Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BIAF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BIAF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIAF Price Earnings VS Forward Price EarningsBIAF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIAF Per share dataBIAF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

BIAF's earnings are expected to grow with 33.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.43%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BIAF!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOAFFINITY TECHNOLOGIES INC

NASDAQ:BIAF (7/29/2025, 3:27:04 PM)

0.328

-0.01 (-2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)08-19 2025-08-19
Inst Owners1.75%
Inst Owner Change0%
Ins Owners16.79%
Ins Owner Change0%
Market Cap9.33M
Analysts43.33
Price Target6.12 (1765.85%)
Short Float %5.53%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-22.55%
Min EPS beat(2)-47.06%
Max EPS beat(2)1.96%
EPS beat(4)1
Avg EPS beat(4)-14.81%
Min EPS beat(4)-47.06%
Max EPS beat(4)1.96%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.14%
Min Revenue beat(2)-13.83%
Max Revenue beat(2)-10.46%
Revenue beat(4)0
Avg Revenue beat(4)-9.41%
Min Revenue beat(4)-13.83%
Max Revenue beat(4)-4.09%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.67%
EPS NY rev (1m)0%
EPS NY rev (3m)11.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)24.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.06
P/FCF N/A
P/OCF N/A
P/B 6.49
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.31
BVpS0.05
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -175.55%
ROE -676.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.41%
FCFM N/A
ROA(3y)-100.74%
ROA(5y)-1117.09%
ROE(3y)-194.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.59
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.49%
Cap/Sales 1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.55
Quick Ratio 0.53
Altman-Z -17.29
F-Score4
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)740.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.33%
EPS Next Y51.22%
EPS Next 2Y33.43%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)78.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-22.97%
Revenue Next Year-32.09%
Revenue Next 2Y-9.73%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32%
OCF growth 3YN/A
OCF growth 5YN/A